首页> 外文期刊>Clinical & translational oncology : >Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?
【24h】

Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?

机译:是否值得将优质肠系膜静脉淋巴结(14V)添加到标准D2胃切除术中的解剖,用于6号淋巴结转移的远端胃癌?

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Radical gastrectomy with D2 lymphadenectomy has been widely recognized as standard surgical procedure for advanced gastric cancer, while the role of No. 14v lymphadenectomy in distal gastric cancer remains controversial. Methods Clinicopathological data of 793 distal gastric cancer patients who underwent at least a radical D2 lymphadenectomy with No. 6 nodes metastasis were retrospectively reviewed. Results Fifty patients received No. 14v lymphadenectomy. Patients with No. 14v nodes metastasis (21/50, 42.0%) had poor prognosis. The No. 14v nodes metastasis was not an independent prognostic factor (P = 0.075). In distal gastric cancer patients with No. 6 nodes metastasis, No. 14v lymphadenectomy deteriorated overall survival, what's more, No. 14v lymphadenectomy was an independent risk prognostic factor (hazard ratio: 1.404; 95% confidence interval 1.043-1.889; P = 0.025). There was no significant difference in overall or locoregional and other types of recurrence rate between the 14vD+ and the 14vD- groups. The proportion of complication rate was greater in 14vD+ group (P = 0.001). Conclusion Extended D2 gastrectomy including No. 14v lymphadenectomy seems to be associated with poor overall survival and increased complication rate of distal gastric cancer patients with No. 6 nodes metastasis.
机译:目的,具有D2淋巴结切除术的激进胃切除术被广泛认为是晚期胃癌的标准外科手术,而14V淋巴结切除术在远侧胃癌中的作用仍存在争议。方法回顾性审查了患有No.6节点转移的793次远端胃癌患者的临床病理学数据。结果50例患者接受14V淋巴结切除术。 14V节点转移患者(21/50,42.0%)预后差。 No.14V节点转移不是独立的预后因子(P = 0.075)。在远端胃癌患者患有6号节点转移的患者中,No.14V淋巴结切除术恶化,总体存活率劣化,更重要的是,14V淋巴结切除术是一个独立的风险预后因子(危险比:1.404; 95%置信区间1.043-1.889; P = 0.025 )。 14VD +和14VD组之间的总体或局部间隙和其他类型的复发率没有显着差异。 14VD +组并发症率的比例更大(P = 0.001)。结论延长D2胃切除术,包括No.14V淋巴结切除术似乎与差的整体存活率差和远端胃癌患者的6号核患者转移相关。

著录项

  • 来源
  • 作者单位

    China Med Univ Affiliated Hosp 1 Dept Surg Oncol 16th Floor 4th Bldg 155 Nanjing North St;

    China Med Univ Affiliated Hosp 1 Dept Surg Oncol 16th Floor 4th Bldg 155 Nanjing North St;

    China Med Univ Affiliated Hosp 1 Dept Surg Oncol 16th Floor 4th Bldg 155 Nanjing North St;

    China Med Univ Affiliated Hosp 1 Dept Surg Oncol 16th Floor 4th Bldg 155 Nanjing North St;

    China Med Univ Affiliated Hosp 1 Dept Surg Oncol 16th Floor 4th Bldg 155 Nanjing North St;

    China Med Univ Affiliated Hosp 1 Dept Surg Oncol 16th Floor 4th Bldg 155 Nanjing North St;

    China Med Univ Affiliated Hosp 1 Dept Surg Oncol 16th Floor 4th Bldg 155 Nanjing North St;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    Gastric cancer; No; 14v lymph node; No; 6 metastasis; Lymphadenectomy; Prognosis;

    机译:胃癌;不;14V淋巴结;不;6转移;淋巴结切除术;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号